Trial will compare rivaroxaban with standard antiplatelet treatment after TAVR

The widely accepted strategy of antiplatelet therapy to stem the risk of thrombosis in the months after transcatheter aortic valve replacement (TAVR) is again being challenged – this time as researchers set out to investigate the effects of a NOAC-based regimen post-TAVR in patients without atrial fibrillation. The study, called GALILEO, will be the first ...

Already a member?

Login to keep reading.

© 2021 the limbic